Anargyros Xenocostas
Overview
Explore the profile of Anargyros Xenocostas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollands C, Boyd A, Zhao X, Reid J, Henly C, ElRafie A, et al.
Cell Rep Med
. 2024 Apr;
5(4):101485.
PMID: 38582086
Despite most acute myeloid leukemia (AML) patients entering remission following chemotherapy, outcomes remain poor due to surviving leukemic cells that contribute to relapse. The nature of these enduring cells is ...
2.
Keow J, Kwan K, Hedley B, Hsia C, Xenocostas A, Chin-Yee B
Int J Lab Hematol
. 2024 Mar;
46(5):761-763.
PMID: 38477102
Bone marrow aspirate showed diffuse infiltration by a population of monomorphic cells with scant cytoplasm, markedly increased nuclear-to-cytoplasmic ratio, and numerous indistinct nucleoli. Bone marrow biopsy confirmed extensive marrow infiltration...
3.
Hillyer A, Quint A, Ghassemian A, Joh-Carnella N, Knauer M, Dawd D, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Feb;
24(5):305-315.
PMID: 38336492
Background: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19...
4.
Perusini M, Novitzky-Basso I, Atenafu E, Forrest D, Bence-Bruckler I, Savoie L, et al.
Br J Haematol
. 2023 Sep;
203(5):781-791.
PMID: 37697469
Multiple studies have reported a significant treatment-free remission (TFR) rate of 50%-60% in patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitor (TKI) therapy. However, the remaining half...
5.
Khadadah F, Cerquozzi S, Olney H, Fraga C, Dudebout J, Xenocostas A, et al.
Leuk Res
. 2023 Sep;
133:107374.
PMID: 37657146
Background: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein. Methods: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022...
6.
Sljivic I, Fulford A, Ho J, Lazo-Langner A, Xenocostas A, Deotare U
Eur J Haematol
. 2023 Aug;
111(6):888-894.
PMID: 37640495
Introduction: The last decade has seen advances in delivering outpatient consolidation therapy for acute myeloid leukemia (AML). The standard of care involves high-dose cytarabine or intermediate-dose cytarabine, given twice daily...
7.
Boyd A, Lu J, Hollands C, Alsostovar L, Murali S, Reid J, et al.
Cell Rep Med
. 2023 Jul;
4(7):101108.
PMID: 37433297
We systematically investigate functional and molecular measures of stemness in patients with acute myeloid leukemia (AML) using a cohort of 121 individuals. We confirm that the presence of leukemic stem...
8.
Novitzky-Basso I, Linn S, White J, Elemary M, Xenocostas A, Deotare U, et al.
Bone Marrow Transplant
. 2023 Jun;
58(9):1024-1032.
PMID: 37365296
Established first-line therapy for chronic graft-versus-host disease (cGvHD) comprises corticosteroids with/without calcineurin inhibitors, but about half of cGvHD patients are refractory to corticosteroid therapy. The present study retrospectively analyzed treatment...
9.
White J, Elemary M, Linn S, Novitzky-Basso I, Culos S, Tan S, et al.
Transplant Cell Ther
. 2022 Dec;
29(2):120.e1-120.e9.
PMID: 36460202
Although ruxolitinib is emerging as the treatment of choice for steroid-refractory or -dependent chronic graft versus host disease (cGVHD) based on randomized control trial data, there is relatively little real-world...
10.
Deschner M, Bastin D, Solh Z, Bosma K, Haddara W, Yang P, et al.
Sci Prog
. 2022 Aug;
105(3):368504221117070.
PMID: 35979627
Graft versus host disease is a rare but deadly complication of solid organ transplant. Clinical features of graft-versus-host-disease are non-specific, which may lead to delayed diagnosis as more common conditions...